Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

Petar M Seferović^{1

2}, Gabriele Fragasso³, Mark Petrie⁴, Wilfried Mullens^{5

6}, Roberto Ferrari⁷, Thomas Thum⁸, Johann Bauersachs⁹, Stefan D Anker^{10

11}, Robin Ray¹², Yuksel Çavuşoğlu¹³, Marija Polovina^{1

14}, Marco Metra¹⁵, Giuseppe Ambrosio¹⁶, Krishna Prasad¹⁷, Jelena Seferović^{1

18}, Pardeep S Jhund¹⁹, Giuseppe Dattilo²⁰, Jelena Čelutkiene²¹, Massimo Piepoli²², Brenda Moura²³, Ovidiu Chioncel^{24

25}, Tuvia Ben Gal²⁶, Stephane Heymans²⁷, Tiny Jaarsma²⁸, Loreena Hill²⁹, Yuri Lopatin³⁰, Alexander R Lyon³¹, Piotr Ponikowski³², Mitja Lainščak^{33

34}, Ewa Jankowska³², Christian Mueller³⁵, Francesco Cosentino³⁶, Lars H Lund³⁷, Gerasimos S Filippatos³⁸, Frank Ruschitzka³⁹, Andrew J S Coats⁴⁰, Giuseppe M C Rosano⁴¹

Affiliations

¹ Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
² Serbian Academy of Sciences and Arts, Belgrade, Serbia.
³ Heart Failure Unit, Clinical Cardiology, University Hospital San Raffaele, Milan, Italy.
⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
⁵ Faculty of Medicine and Life Sciences, BIOMED - Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
⁶ Department of Cardiology, Ziekenhuis Oost, Genk, Belgium.
⁷ Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, ES Health Science Foundation, Cotignola, Italy.
⁸ Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany.
⁹ Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany.
¹⁰ Department of Cardiology (CVK), Berlin Institute of Health Centre for Regenerative Therapies (BCRT), Berlin, Germany.
¹¹ German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK.
¹³ Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.
¹⁴ Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia.
¹⁵ Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
¹⁶ Division of Cardiology, University of Perugia, Perugia, Italy.
¹⁷ United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK.
¹⁸ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre, Belgrade, Serbia.
¹⁹ British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
²⁰ Department of Clinical and Experimental Medicine, University of Messina, Cardiology Unit, Messina, Italy.
²¹ Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
²² Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy.
²³ Hospital das Forças Armadas and Cintesis- Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
²⁴ University of Medicine Carol Davila, Bucharest, Romania.
²⁵ Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
²⁶ Department of Cardiology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁷ Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
²⁸ Department of Social and Welfare Studies, Faculty of Health Science, Linköping University, Linköping, Sweden.
²⁹ School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
³⁰ Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation.
³¹ National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, UK.
³² Centre for Heart Diseases, Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland.
³³ Department of Internal Medicine, and Department of Research and Education, General Hospital Murska Sobota, Murska Sobota, Slovenia.
³⁴ Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
³⁵ Department of Cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.
³⁶ Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
³⁷ Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
³⁸ National and Kapodistrian University of Athens, School of Medicine, University Hospital Attikon, Athens, Greece.
³⁹ Department of Cardiology, University Heart Center, Zürich, Switzerland.
⁴⁰ Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.
⁴¹ Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.

PMID: 33068051
DOI: 10.1002/ejhf.2026

Free article

Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

Petar M Seferović et al. Eur J Heart Fail. 2020 Nov.

Free article

. 2020 Nov;22(11):1984-1986.

doi: 10.1002/ejhf.2026. Epub 2020 Oct 27.

Authors

Affiliations

¹ Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
² Serbian Academy of Sciences and Arts, Belgrade, Serbia.
³ Heart Failure Unit, Clinical Cardiology, University Hospital San Raffaele, Milan, Italy.
⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
⁵ Faculty of Medicine and Life Sciences, BIOMED - Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
⁶ Department of Cardiology, Ziekenhuis Oost, Genk, Belgium.
⁷ Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, ES Health Science Foundation, Cotignola, Italy.
⁸ Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany.
⁹ Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany.
¹⁰ Department of Cardiology (CVK), Berlin Institute of Health Centre for Regenerative Therapies (BCRT), Berlin, Germany.
¹¹ German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK.
¹³ Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.
¹⁴ Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia.
¹⁵ Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
¹⁶ Division of Cardiology, University of Perugia, Perugia, Italy.
¹⁷ United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK.
¹⁸ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre, Belgrade, Serbia.
¹⁹ British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
²⁰ Department of Clinical and Experimental Medicine, University of Messina, Cardiology Unit, Messina, Italy.
²¹ Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
²² Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy.
²³ Hospital das Forças Armadas and Cintesis- Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
²⁴ University of Medicine Carol Davila, Bucharest, Romania.
²⁵ Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
²⁶ Department of Cardiology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁷ Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
²⁸ Department of Social and Welfare Studies, Faculty of Health Science, Linköping University, Linköping, Sweden.
²⁹ School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
³⁰ Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation.
³¹ National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, UK.
³² Centre for Heart Diseases, Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland.
³³ Department of Internal Medicine, and Department of Research and Education, General Hospital Murska Sobota, Murska Sobota, Slovenia.
³⁴ Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
³⁵ Department of Cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.
³⁶ Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
³⁷ Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
³⁸ National and Kapodistrian University of Athens, School of Medicine, University Hospital Attikon, Athens, Greece.
³⁹ Department of Cardiology, University Heart Center, Zürich, Switzerland.
⁴⁰ Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.
⁴¹ Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.

PMID: 33068051
DOI: 10.1002/ejhf.2026

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

Keywords: Cardiovascular outcomes; Heart failure; Renal function; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus.

PubMed Disclaimer

Cited by

Heart failure: an update from the last years and a look at the near future.
Riccardi M, Sammartino AM, Piepoli M, Adamo M, Pagnesi M, Rosano G, Metra M, von Haehling S, Tomasoni D. Riccardi M, et al. ESC Heart Fail. 2022 Dec;9(6):3667-3693. doi: 10.1002/ehf2.14257. ESC Heart Fail. 2022. PMID: 36546712 Free PMC article. Review.
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
Voorrips SN, Saucedo-Orozco H, Sánchez-Aguilera PI, De Boer RA, Van der Meer P, Westenbrink BD. Voorrips SN, et al. Int J Mol Sci. 2022 Aug 3;23(15):8631. doi: 10.3390/ijms23158631. Int J Mol Sci. 2022. PMID: 35955784 Free PMC article. Review.
Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.
Njoroge JN, Teerlink JR. Njoroge JN, et al. Circ Res. 2021 May 14;128(10):1468-1486. doi: 10.1161/CIRCRESAHA.121.318186. Epub 2021 May 13. Circ Res. 2021. PMID: 33983837 Free PMC article. Review.
Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom.
Seferovic PM, Polovina M, Milinkovic I, Anker S, Rosano G, Coats A. Seferovic PM, et al. Int J Heart Fail. 2021 May 26;3(4):205-218. doi: 10.36628/ijhf.2021.0013. eCollection 2021 Oct. Int J Heart Fail. 2021. PMID: 36262556 Free PMC article. Review.
Heart failure drug treatment: the fantastic four.
Bauersachs J. Bauersachs J. Eur Heart J. 2021 Feb 11;42(6):681-683. doi: 10.1093/eurheartj/ehaa1012. Eur Heart J. 2021. PMID: 33447845 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, de Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJ, Rosano GM. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:1495-1503.
1. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZ, McGuire D; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383:1425-1435.
1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-la Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424.
1. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819-829.
1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray J, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

Affiliations

Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

Authors

Affiliations

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous